Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: A major challenge

Arthritis Research and Therapy

Volumn 12, Issue 1, 2010, Pages

  Bultink, Irene E M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PHOSPHOLIPID ANTIBODY; VON WILLEBRAND FACTOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; EDITORIAL; PROSPECTIVE STUDY; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; HUMAN; NOTE;

CARDIOVASCULAR DISEASES; COHORT STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 77649297364     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2927     Document Type: Editorial

References (11)

1. Gustafsson J, Gunnarsson I, Börjesson O, Petterson S, Möller S, Guo-Zhong F, Elvin K, Simard JF, Hansson L-O, Lundberg IE, Larsson A, Svenungsson E. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther 2009, 11:R186. 10.1186/ar2878, 20003285.
2. Toloza SM, Uribe AG, McGwin G, Alarcón GS, Fessler BJ, Bastian HM, Vilá LM, Wu R, Shoenfeld Y, Roseman JM, Reveille JD, . for the LUMINA Study Group Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50:3947-3957. 10.1002/art.20622, 15593203, for the LUMINA Study Group.
3. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus. A comparison of three ethnic groups. Arthritis Rheum 2005, 52:2774-2782. 10.1002/art.21224, 16142761.
4. Urowitz MB, Ibanez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: Prevalence and risk factors. J Rheumatol 2007, 34:70-75.
5. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae S-C, Isenberg D, Zoma A, Aranow C, Dooley M-A, Nived O, Sturfelt G, Steinsson K, Alarcón G, Senécal J-L, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2550-2557. 10.1002/art.21955, 16868977.
6. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côté R, Grover SA, Fortin PR, Clarke A, Senécal J-L. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337. 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I, 11665973.
7. Spiel AO, Gilbert JC, Jilma B. Von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008, 117:1449-1459. 10.1161/CIRCULATIONAHA.107.722827, 18347221.
8. de Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 2006, 15:675-682. 10.1177/0961203306069972, 17120595.
9. Lindsey NJ, Dawson RA, Henderson FI, Greaves M, Hughes P. Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome. Br J Rheumatol 1993, 32:123-126. 10.1093/rheumatology/32.2.123, 8428224.
10. Lai KN, Leung JCK, Lai KB, Lai FM, Wong KC. Increased release of von Willebrand factor antigen from endothelial cells by anti-DNA autoantibodies. Ann Rheum Dis 1996, 55:57-62. 1010083, 8572736, 10.1136/ard.55.1.57.
11. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004, 114:593-595. 10.1016/j.thromres.2004.07.012, 15507296.